Ignite Creation Date:
2024-05-05 @ 12:02 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00222144
Status:
COMPLETED
Last Update Posted:
2012-08-07
First Post:
2005-09-13
Brief Title:
Study of Gleevec and Taxotere in Recurrent Non-Small Cell Lung Cancer
Sponsor:
University of Kansas
Organization:
University of Kansas Medical Center
Study Overview
Official Title:
Phase II Study of Gleevec and Taxotere in Recurrent Non-Small Cell Lung Cancer
Status:
COMPLETED
Status Verified Date:
2012-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary goal of this study is to determine the effects of the combination of Gleevec and Taxotere in lung cancer in terms of control and reduction of the cancer size The study will also test lung cancer to see if the presence of certain protein called receptor for platelet derived growth factor can influence the effect of the treatment
Detailed Description:
The purpose of this study is to evaluate the response rate of Gleevec with Taxotere in patients with recurrent non-small cell lung cancer Also to determine the expression of PDGF-R phosphorylated PDGF-r and C-kit in the original tissue and correlate with response If the patient has a tumor in an accessible location we will ask for consent from the patient to obtain biopsy before and after the therapy to assess the same molecular markers
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None